Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc. The submission status …
-
FDA approval · 2021-12-14FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc, resulting in updated …
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: Study of Cimzia for the Treatment of Ulcerative Colitis [Phase 2]
Phase 2 trial update for Cimzia in ulcerative colitis has completed.
-
FDA approval · 2021-12-06FDA Approved: MESALAMINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Mesalamine from Actavis Pharma, Inc. (generic Mesalamine).
-
FDA approval · 2021-12-02FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc. The approval authorizes the ex…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]
Phase 3 trial update evaluating the efficacy and safety of Upadacitinib (ABT-494) in moderately to severely active ulcerative colitis comple…
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis [Phase 2]
Extension study results for APD334-003 in moderately to severely active ulcerative colitis completed with results posted.
-
FDA approval · 2021-11-18FDA Approved: MESALAMINE — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for mesalamine by Zydus Lifesciences Limited, updating or expanding its labeling.
-
CLINICAL_TRIALS trial_result · 2021-11-11Clinical Trial Update: Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis [Phase 4]
Phase 4 trial updating intravenous dose optimization of vedolizumab in ulcerative colitis has completed with results posted.
-
FDA approval · 2021-11-01FDA Approved: PENTASA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA has approved a supplemental application for Pentasa (mesalamine) from Takeda Pharmaceuticals America, resulting in an updated labeli…
-
FDA approval · 2021-11-01FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approves a supplemental application for CANASA (mesalamine) by Allergan, Inc.
-
FDA approval · 2021-11-01FDA Approved: DIPENTUM — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Dipentum (olsalazine sodium) from Viatris Specialty LLC.
-
FDA approval · 2021-11-01FDA Approved: MESALAMINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for mesalamine filed by ANI Pharmaceuticals, Inc.
-
FDA approval · 2021-11-01FDA Approved: MESALAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for mesalamine from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2021-11-01FDA Approved: LIALDA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for LIALDA (mesalamine) submitted by Takeda Pharmaceuticals America, expanding the approved labeling…
-
FDA approval · 2021-11-01FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Azulfidine EN-Tabs (sulfasalazine) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2021-10-15FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC. The approval…
-
CLINICAL_TRIALS trial_result · 2021-10-07Clinical Trial Update: A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy [Phase 2]
A Phase 2 study evaluated whether adding BI 655130 to patients' TNF inhibitor therapy improves bowel inflammation in mild to moderate ulcera…
-
CLINICAL_TRIALS trial_result · 2021-10-01Clinical Trial Update: Faecal Bacteriotherapy for Ulcerative Colitis [Phase 2]
Phase 2 trial update on faecal bacteriotherapy for ulcerative colitis has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-01Clinical Trial Update: Curcumin in Pediatric Ulcerative Colitis [Phase 3]
Phase 3 trial of curcumin in pediatric ulcerative colitis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-09-17Clinical Trial Update: Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis [Phase 3]
Phase 3 long-term study update for CP-690,550 in ulcerative colitis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC) [Phase 3]
Phase 3 trial update on mesalamine 2 g sachet for maintaining remission in ulcerative colitis; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis [Phase 3]
Phase 3 trial assessing safety and efficacy of RPC1063 in moderate to severe ulcerative colitis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). [Phase 3]
Phase 3 trial comparing combination corticosteroids with 5-aminosalicylic acids versus corticosteroids alone for ulcerative colitis has comp…
-
FDA approval · 2021-08-17FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.